Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8133145 | 0.84 | CYP3A4 (0.59) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL12442612 | 0.83 | CYP3A4 (0.58) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL31087166 | 0.83 | CYP3A4 (0.58) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL28254880 | 0.81 | CYP3A4 (0.56) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL2217005 | 0.80 | SMN1; SMN2 (0.56) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL13772554 | 0.80 | CYP3A4 (0.63) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL27490427 | 0.80 | GAA (0.61) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| Ethylene SCHEMBL8381698 | 0.78 | GAA (0.58) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL15825669 | 0.78 | CYP3A4 (0.53) | CYP3A4HSD17B10GAAALDH1A1HPGD | |
| SCHEMBL3758802 | 0.78 | CYP3A4 (0.52) | CYP3A4HSD17B10GAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3127912-B1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | UNIV ZHEJIANG (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-9856288-B2 | Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof | ZHEJIANG UNIVERSITY (CN) | 2018-01-02 | — | — | US | disclosed |
| EP-3127912-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | Zhejiang University (CN) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022250-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA , CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-26 | — | — | US | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-101636398-A | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions | XENON PHARMACEUTICALS INC | 2010-01-27 | — | — | CN | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022250-A1 | TRIPEPTIDE EPOXYKETONE COMPOUND CONSTRUCTED BY HETEROCYCLE AND PREPARATION METHOD AND USE THEREOF | VIP, DNPEP, PREP | CYP3A4 1016/4885HSD17B10 1011/4885GAA 2365/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | CYP3A4 1811/4885HSD17B10 3557/4885GAA 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.